Evidence map›Paper›PMID 41602889›Full record

ArticleFrontiers in pediatrics2025

Outcomes of T-cell lymphoblastic lymphoma in children and adolescents treated with Dana-Farber Cancer Institute Childhood ALL Consortium protocols.

Giacomo Gotti, Yael Flamand, Victoria Koch, Sabrina Testa, Kristen Stevenson, Thai-Hoa Tran, Bruno Michon, Uma Athale, Lewis B Silverman, Yana Pikman and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Giacomo GottiDepartment of Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
Yael FlamandDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, United States.
Victoria KochDana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, United States.
Sabrina TestaDepartment of Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
Kristen StevensonDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, United States.
Thai-Hoa TranDivision of Pediatric Hematology-Oncology, Charles-Bruneau Cancer Center, CHU Sainte-Justine, Université de Montréal, Montréal, QC, Canada.
Bruno MichonDivision of Pediatric Hematology-Oncology, CHU de Quebec, Saint-Foy, QC, Canada.
Uma AthaleDivision of Hematology Oncology, McMaster Children's Hospital, and Department of Pediatrics, McMaster University, Hamilton, ON, Canada.
Lewis B SilvermanDivision of Pediatric Hematology, Oncology and Stem Cell Transplantation, Columbia University Medical Center, New York, NY, United States.
Yana Pikman *Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, United States.
Andrew E Place *Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment approaches to childhood T-cell lymphoblastic lymphoma (T-LL) are based on those used for T-cell acute lymphoblastic leukemia (T-ALL), but reports of outcomes with contemporary regimens are limited, as patients with LL are often excluded from ALL clinical trials. In this study, we retrospectively analyzed the characteristics and outcome of a cohort of 23 pediatric patients with T-LL treated between 2006 and 2020 according to Dana-Farber Cancer Institute (DFCI) ALL Consortium protocols. Five-year event-free survival, overall survival, and disease-free survival rates were 78.3% (95% CI: 55.4%-90.3%), 87.0% (95% CI: 64.8%-95.6%), and 90% (95% CI: 65.6%-97.4%), respectively. Morphological marrow disease (defined as 5%-24% blasts) at diagnosis was the only feature associated with adverse prognosis. Treatment based on DFCI ALL protocols is an effective strategy for childhood LL and should be considered at the time of treatment selection.

Indexed as

Lymphoblastic lymphomaoutcomesprognostic factorsT-cell lymphoblastic lymphomatreatment protocols

Identifiers

PMID41602889
PMCPMC12833020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.